Pseudovirion-binding and neutralizing antibodies to cutaneous human papillomaviruses (HPV) correlated with the presence of HPV DNA in skin.
Whereas the antibody response to the anogenital human papillomaviruses (HPVs) is known to be mainly type-specific, correlated with the presence of viral DNA and mainly directed to conformational epitopes of the virion, it is not known if this applies also to the antibody response to cutaneous HPVs. For 434 non-immunosuppressed patients with skin lesions (squamous cell carcinoma and basal cell carcinoma of the skin, actinic keratosis and benign skin lesions), we compared HPV DNA status with seroreactivity to HPV pseudovirions (PsV) and to GST-L1 fusion proteins from HPV types -5, -6, -15, -16, -32 and -38. Biopsies from the skin lesions were tested for the presence of HPV DNA using three different PCR methods, with typing by sequencing. Serum samples from subjects with HPV DNA-positive biopsies and randomly selected serum samples from subjects with HPV DNA-negative biopsies were also tested with neutralization assays with HPV5, -38 and -76 PsV. Agreement of the three serological methods varied from poor to moderate. Type-specific seroprevalences among patients positive for the same type of HPV DNA (sensitivity of serology) was improved with the PsV-based method (mean of 40%, maximum 63%) compared with the GST-L1 method (mean of 20%, maximum of 25%). Neutralization was the most sensitive assay for HPV38 (50%). In summary, cutaneous HPVs also appear to induce a type-specific antibody response that correlates with the presence of HPV DNA and that can be detected with improved sensitivity using PsV-based serology.
Department of Laboratory Medicine, Skåne University Hospital, Lund University, Malmö, Sweden.
Helena
H
Faust
Department of Laboratory Medicine, Skåne University Hospital, Lund University, Malmö, Sweden.
Kristin
K
Andersson
Department of Laboratory Medicine, Skåne University Hospital, Lund University, Malmö, Sweden.
Ola
O
Forslund
Departments of Laboratory Medicine, Medical Epidemiology & Biostatistics, Karolinska Institutet and Departments of Clinical Microbiology and Pathology, Karolinska Hospital, Stockholm, Sweden.|Department of Laboratory Medicine, Skåne University Hospital, Lund University, Malmö, Sweden.
Joakim
J
Dillner
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D001317:Austria / Q000453:epidemiology; D001706:Biopsy; D002280:Basal Cell Carcinoma / Q000453:epidemiology / Q000821:virology*; D002294:Carcinoma, Squamous Cell / Q000453:epidemiology / Q000821:virology*; D016022:Case-Control Studies; D004279:DNA, Viral / Q000235:genetics*; D006801:Humans; D055623:Keratosis, Actinic / Q000453:epidemiology / Q000821:virology*; D008875:Middle Aged; D027383:Papillomaviridae / Q000235:genetics* / Q000276:immunology / Q000378:metabolism; D016036:Seroepidemiologic Studies; D012867:Skin / Q000821:virology; D012878:Skin Neoplasms / Q000453:epidemiology / Q000821:virology*; D013045:Species Specificity; D013548:Sweden / Q000453:epidemiology
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D004279:DNA, Viral